Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Dupilumab (Dupixent) becomes first FDA-approved drug for adolescent CRSwNP
FDA expands approval of dupilumab (Dupixent) to treat chronic rhinosinusitis with nasal polyps (CRSwNP) in adolescents aged 12-17, based on clinical trial data showing significant improvements in nasal congestion, polyp size, and sense of smell, reducing need for systemic corticosteroids or surgery.
Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer
R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.
France's First 4.0 Sustainable MedTech Facility
MGA MedTech inaugurates a fully digitalized, robotized, and sustainable 4.0 factory in Mably, France, dedicated to advancing in vitro diagnostics and cellular and gene therapies. The facility integrates cutting-edge technology with eco-friendly practices, positioning MGA MedTech as a key player in medical technologies and sustainable industrial development.
Dupixent Approval Expanded to Include Adolescent Patients With CRSwNP
FDA expands Dupixent® approval for add-on maintenance treatment of adolescents aged 12-17 with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP), based on phase 3 trials showing significant reductions in nasal polyp size, nasal congestion, and systemic corticosteroid use in adults.
FDA Approves Dupilumab Label Expansion with Indication for CRSwNP in Adolescents
The FDA approved dupilumab (Dupixent) as add-on maintenance therapy for adolescents aged 12-17 with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP), marking the first biologic treatment for this age group. Dupilumab, a monoclonal antibody targeting IL-4 and IL-13 pathways, significantly improves symptoms and reduces the need for systemic corticosteroids or surgery, with a safety profile consistent with its known effects.
Sanofi signs global rights deal to develop rare cancer therapy
Genzyme accuses Sarepta of infringing on gene therapy patents with Elevidys; despite the dispute, Elevidys achieves $200M in sales and FDA approvals.
Subcutaneous Tecentriq gets FDA OK; Gilead shot succeeds in second HIV trial
Roche's subcutaneous Tecentriq approved for cancer treatment; Gilead's twice-yearly HIV shot reduces infection risk by 96%; Biogen appoints Lloyd Minor and Menelas Pangalos as independent directors; Sanofi secures rights to a rare cancer radiopharmaceutical; Eli Lilly to expand Irish manufacturing for Alzheimer's drug Kisunla.
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents
Dupixent approved by FDA for adolescents aged 12-17 with inadequately controlled CRSwNP, offering an alternative to standard treatments that often fail to control symptoms and prevent nasal polyp recurrence.
Dupixent Approved in the US as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps
FDA approves Dupixent for adolescents aged 12-17 with chronic rhinosinusitis with nasal polyps, expanding its initial 2019 approval for adults.
© Copyright 2025. All Rights Reserved by MedPath